Targeting of Receptor Activator of Nuclear Kappa B (RANK) in PC-3 cells increases cell proliferation and matrix adhesion in vitro.

Owen, Sioned, Sanders, Andrew J. ORCID: https://orcid.org/0000-0002-7997-5286, Mason, Malcolm David ORCID: https://orcid.org/0000-0003-1505-2869 and Jiang, Wen Guo ORCID: https://orcid.org/0000-0002-3283-1111 2016. Targeting of Receptor Activator of Nuclear Kappa B (RANK) in PC-3 cells increases cell proliferation and matrix adhesion in vitro. Anticancer Research 36 (3) , pp. 1127-1134.

Full text not available from this repository.

Abstract

BACKGROUND: In Western societies, prostate cancer is the most frequently diagnosed cancer amongst men. Efforts to improve diagnosis and treatment remain a major focus and have been proven beneficial in the approach to localised disease. However, currently, metastatic disease management still remains palliative. Receptor activator of nuclear kappa B (RANK) has been extensively studied in bone biology and immunology, whilst several links have been made between RANK-positive breast cancer cells and disease progression. Its role in prostate cancer biology remains poorly understood, therefore the aim of this study was to explore the functional role of endogenously produced RANK in metastatic PC-3 prostate cancer cells in isolation and in response to hepatocyte growth factor (HGF). MATERIALS AND METHODS: RANK expression was targeted using hammerhead ribozyme technology in PC-3 prostate cancer cells, and verified by polymerase chain reaction and western blot. A variety of in vitro functional assays were conducted, including cell proliferation and matrix adhesion in the presence of HGF. RESULTS: Suppression of RANK expression was successfully targeted with anti-RANK hammerhead ribozyme transgenes, as verified by PCR and western blot. Reduced RANK expression resulted in significantly increased PC-3 cell proliferation (p<0.01) and cell-matrix adhesion (p<0.05) compared to control cells. CONCLUSION: Previous work into RANK and prostate cancer has focused on its interaction with the bone environment, particularly with regard to its receptor RANK ligand. This study has shown that endogenous RANK expression changes might also influence prostate cancer cell behaviour. Further work is now required to elucidate the signaling pathways involved in these processes.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Subjects:	R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Publisher:	International Institute of Anticancer Research
ISSN:	0250-7005
Funders:	Cancer Research Wales
Date of Acceptance:	18 February 2016
Last Modified:	01 Nov 2022 09:29
URI:	https://orca.cardiff.ac.uk/id/eprint/88109

Actions (repository staff only)

Edit Item